Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CombiRT: Dabrafenib, Trametinib, and Radiotherapy in BRAF-mutant Melanoma
NCT02392871Phase 2Completed
- Start
- May 2015
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in cutaneous melanoma (CM). Started May 2015; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT02392871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392871.